Protagonist and takeda announce positive topline results from phase 3 verify study of rusfertide in patients with polycythemia vera

Newark, calif. & osaka, japan & cambridge, mass.--(business wire)--protagonist therapeutics, inc. (“protagonist”) (nasdaq:ptgx) and takeda (tse:4502/nyse:tak) today announced positive topline results for the phase 3 verify study, in which phlebotomy-dependent patients with polycythemia vera (pv) were randomized to treatment with either rusfertide or placebo, as an add-on to standard of care treatment. the study met its primary endpoint and all four key secondary endpoints. rusfertide is a first.
TAK Ratings Summary
TAK Quant Ranking